AIM: To study curative effect of Ranibizumab with Ex-PRESS drainage device for neovascular glaucoma.

METHODS: From January 2012 to December 2014 in our hospital, 51 cases(62 eyes)with neovascular glaucoma were enrolled as the research objects. Under the unified enrolling criteria and measuring methods, according to the actual clinical situation and combined with the doctor's judgment, the patients were divided into control group with 23 cases(28 eyes)and observation group with 28 cases(34 eyes). The patients in observation group received the injection of ranibizumab combined the Ex-PRESS drainage device implantation. The patients in control group were only given the Ex-PRESS drainage device implantation. The vision, intraocular pressure(IOP)before and after treatments were compared as well as the outcomes and incidences of adverse reactions of the two groups.

RESULTS: Before treatments, IOP of the two groups did not have statistically significant different(P>0.05). After treatments, IOP of the two groups were significantly lower, and the differences were statistically significant(P<0.05), and the IOP of the observation group at 1, 4wk after treatments were significantly lower than those of the control group, and the differences were statistically significant(P<0.05). Before treatments, the visual acuity of the two groups did not have statistically significant difference(P>0.05). After treatments, the visual acuity of the control group improved in 2 cases(3 eyes), didn't change in 18 cases(22 eyes), and declined in 3 cases(3 eyes). While the visual acuity of observation group improved in 12 cases(12 eyes), didn't change in 15 cases(21 eyes), and declined in 1 case(1 eye). The distribution of the visual acuity of the two groups was significantly different(P<0.05). The effective rate of observation group was 85.3%, and that of control group was 60.7%. The difference between the two groups was statistically significant(P<0.05). In the observation group, there were 4 cases(4 eyes)with hyphema, 2 cases(2 eyes)with decompensation of corneal endothelial function and the incidence of postoperative complications was 18%. In the control group, there were 3 cases(3 eyes)with corneal edema and the incidence of postoperative complications was 11%. There was no statistically significant difference on the incidence of postoperative complications between the two groups(P>0.05).

CONCLUSION: For patients with neovascular glaucoma, the injection of ranibizumab combined with the Ex-PRESS the drainage device implantation can effectively reduce IOP, improve visual function in patients with impaired visual function or delay the recession of visual function, with outstanding curative effect, high security features and is worthy of clinical application.